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Human adipose-derived stem cells (hASC) are now a prevalent source of adult stem cells for studies in tissue
engineering and regenerative medicine. However, researchers utilizing hASC in their investigations often
encounter high levels of donor-to-donor variability in hASC differentiation potential. Because of this, con-
ducting studies with this primary cell type can require extensive resources to generate statistically significant
data. We present a method to generate pooled donor cell populations, termed ‘‘superlots,’’ containing cell
populations derived from four to five age-clustered donors. The goal of generating these superlots was to
1) increase experimental throughput, 2) to utilize assay resources more efficiently, and 3) to begin to establish
global hASC differentiation behaviors that may be associated with donor age. With our superlot approach, we
have validated that pooled donor cell populations exhibit proliferative activity representing the combined
behavior of each individual donor cell line. Further, the superlots also exhibit differentiation levels roughly
approximating the average combined differentiation levels of each individual donor cell line. We established
that high donor-to-donor variability exists between the pre-, peri-, and postmenopausal age groupings and that
proliferation and differentiation characteristics can vary widely, independent of age. Interestingly, we did
observe that cell lines derived from postmenopausal donors demonstrated a relatively high proclivity for
osteogenic differentiation and a relatively lowered proclivity for adipogenic differentiation as compared with
cells derived from pre- and perimenopausal donors. In general, superlots effectively represented the average
differentiation behavior of each of their contributing cell populations and could provide a powerful tool for
increasing experimental throughput to more efficiently utilize resources when studying hASC differentiation.
Introduction
The study of human adipose-derived stem cells (hASC)has been a rapidly expanding area of research due to
the potential implementation of hASC in a wide range of
clinical applications. Both in vitro and in vivo studies
have demonstrated the ability of these cells to differentiate
into a variety of mesodermal lineages such as adipogenic,
osteogenic, chondrogenic, myogenic, and vasculogenic cell
types.1–5 Despite their multilineage differentiation potential,
hASC exhibit a high level of donor-to-donor variability.6–9
This particular characteristic presents a challenge for
studying and manipulating hASC on the bench top, as well
as employing their widespread use in regenerative medicine
applications in the clinic.
With this high level of donor variability, it is necessary to
consider the possible sources of donor-specific hASC differ-
entiation capacity when selecting appropriate experimental
donor cell lines. To obtain data representing the consensus
behavior of differentiating hASC, it is critical to incorporate
both experimental technical replicates within each donor
cell line and use the statistically appropriate number of do-
nors. Generating this data can become quite experimentally
expensive and may not yield reports of consensus data, as
accessible patient history is often limited to gender and age.
Furthermore, this experimental challenge translates into a
1Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, North Carolina State University, Raleigh,
North Carolina.
2Department of Materials Science and Engineering, North Carolina State University, Raleigh, North Carolina.
TISSUE ENGINEERING: Part C
Volume 20, Number 12, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/ten.tec.2013.0683
972
larger clinical barrier to understanding how to appropriately
utilize hASC in a regenerative medicine capacity.
To circumvent the need to run multiple replicates for
various cell lines derived from individual donors, some
laboratories and companies now generate pooled cell lines
derived from a number of donors, termed ‘‘superlots’’, in
their studies.10,11 The rationale for superlots, or pooled do-
nor cell lines, is that the number of samples necessary to
generate consensus data on hASC differentiation behavior
can be minimized. However, this method of pooling cell
lines has not been thoroughly investigated. It is well es-
tablished that age affects the stem cell activity in vivo and
in vitro; however, characterizing potency changes in aging
stem cells is a complex process.9,12–15 A number of inves-
tigators have reported conflicting data on whether adi-
pose and/or mesenchymal stem cell potency varies with
age.9,12,16,17 This may be due to variations in donor health,
isolation, and culture procedures, but may also depend on
the assays used for characterization. Further complicating
the consensus data in the application of hASC for mus-
culoskeletal tissue engineering, investigators have reported
that mesenchymal and adipose-derived stem cells isolated
from patients or animal models of osteoarthritis have full
capacity to differentiate into osteogenic, chrondrogenic,
and adipogenic tissues.18,19 Additionally, there is evidence
that rabbit ASC derived from osteoporotic rabbits have a
comparable capacity for in vitro osteogenic differentiation as
compared with healthy rabbits, suggesting that a disease such
as osteoporosis does not preclude the use of ASC in autol-
ogous therapies.20 However, what a majority of investigators
do agree upon is that high donor-to-donor variability is a
barrier to understanding the consensus behaviors of hASC
differentiation and, moreover, a barrier to their widespread
clinical use.
In this study, we present a method by which we generate
hASC superlots derived from four to five individual donors
per superlot group, with each group delineated by age, with
the goal of further understanding and potentially stream-
lining research approaches in studying hASC for tissue en-
gineering applications. The donor lines were clustered based
on the estimated average age of menopause in Western
societies being 51 years.21 As all the donors were female,
they were generally categorized into three age groups based
on the availability of cells in a specific donor range in our
cell bank: premenopausal (24–36 years), perimenopausal
(48–55 years), and postmenopausal (60–81 years). It is
important to note that the ages and number of donor cell
lines incorporated in this study were based on the avail-
ability of donor cell lines within our laboratory bank of
cells. Due to isolating and maintaining our own cell bank,
the number of contributing donor cell lines and the range of
ages incorporated are limitations of this study. Our overall
objective was to present a method for generating hASC
superlots, and to validate the approach of generating age-
matched pooled samples to obtain consensus data on age-
matched hASC.
Materials and Methods
hASC isolation and propagation
hASC were isolated from excess adipose tissue derived
from anonymous patients undergoing elective surgery (Of-
fice of Human Research at UNC, IRB exemption protocol
#10-0201), at the University of North Carolina hospitals
(Chapel Hill, NC). Anonymous patient data obtained in-
cluded age, gender, ethnicity, and the procedure from which
the tissue was collected. Isolation of hASC was performed
according to previously established protocols from our lab-
oratory,22 adapted from methods initially reported by Zuk
et al.2 Once hASC were extracted from *50 g of tissue, they
were allowed to propagate in culture in a complete growth
medium (CGM) until *80% confluency (or up to 2 weeks).
Cells were expanded in the CGM containing Minimum Es-
sential Medium, alpha modified supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL
penicillin, and 100mg/mL streptomycin. The hASC were
then trypsinized and frozen down at passage 0 (p0). All
hASC used in these experiments were derived from female
donors (ages 24–81 years).
Potency characterization: osteogenic, adipogenic,
and chondrogenic differentiation
At the time of each individual donor hASC isolation, the
cell isolates were characterized based on their growth and
differentiation potential. Each donor cell line was char-
acterized as p0 cells and cultured in the CGM, adipogenic
differentiation medium (ADM), and osteogenic differen-
tiation medium (ODM). Differentiation media contained
inductive supplements to the aforementioned CGM. The
ADM was composed of the CGM combined with 1 mM
dexamethasone, 5 mg/mL h-insulin, 100 mM indometha-
cin, and 500 mM isobutylmethylxanthine. The ODM was
composed of the CGM with the addition of 50 mM
ascorbic acid, 0.1 mM dexamethasone, and 10 mM b-
glycerolphosphate.
To assess multipotency, p0 hASC were grown in each
medium condition for 14 days. Staining and monitoring of
morphological changes through microscopy were used to
evaluate the adipogenic and osteogenic differentiation po-
tential. Cells were seeded in six-well plates (5 · 104 cells/
well) and were grown to 90–100% confluency in the CGM
(1–3 days). Upon confluency, hASC were cultured in their
treatment media, ODM or ADM (14 days), for osteogenic or
adipogenic differentiation induction, respectively, as well as
the CGM for a baseline comparison. Evidence of differen-
tiation was visualized with phase-contrast microscopy and
using Alizarin Red S for calcium accumulation (osteogen-
esis) and Oil Red O for lipid droplet accumulation (adipo-
genesis) as visualized on a dissecting microscope (Leica
Microsystems, Inc.). Cross staining of Alizarin Red S in
ADM- and CGM-treated wells and Oil Red O staining in
ODM- and CGM-treated wells was performed to ensure
that hASC yield an appropriate differentiation response
(Fig. 1). Any cell lines that exhibited aberrant staining such
as lipid accumulation under culture with the osteogenic
induction medium or calcium accretion under culture with
the adipogenic induction medium were excluded.
For an expanded study of multipotency, we also char-
acterized our hASC lines for their chondrogenic differen-
tiation potential. To induce chondrogenesis, hASC were
cultured in chondrogenic induction media (Dulbecco’s
Modified Eagle’s media, high glucose without glutamine,
supplemented with 1% FBS, 100 U/mL penicillin, 100mg/mL
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streptomycin, 4 mM L-glutamine, 6.25mg/mL h-Insulin,
10 ng/mL transforming growth factor-b3, and 50 nM ascor-
bate-2-phosphate) for 3–4 weeks and were fixed, embedded
in paraffin, and sectioned for analysis. Sections of the pellets
were stained with Safranin O or Alcian Blue to characterize
levels of hASC chondrogenesis (data not shown).
Age-matched approach to hASC superlots
It is well known that bone density changes with age.
Furthermore, during and after menopause, a decrease in
bone density is frequently observed. Additionally, the de-
velopment of osteoporosis is often associated with the oc-
currence of menopause.23 Therefore, in an attempt to take
this information into consideration, we generated pooled
donor hASC superlots. We categorized donor groups by the
average reported ages of pre-, peri-, and postmenopausal
women.21 The premenopausal superlot was composed of
cells derived from donors of age 24–36 years, the perime-
nopausal superlot was composed of cells derived from do-
nors of age 48–55 years, and the postmenopausal superlot
was composed of cells derived from donors of age 60–81
years. It should, however, be noted that these groupings
were based on average reported data and the availability of
donor cells within each age group, and were not selected
based on the reported menopausal phase of the specific
donor as that information was not, and is not typically, re-
ported with the anonymous patient data.
Generating hASC superlots
The goal of creating a hASC superlot is to increase the
throughput of experimental data, to acquire true consensus
hASC growth and differentiation characteristics to best
harness their potential for clinical applications, and to stream-
line the bench-to-bedside process to produce hASC-derived
therapeutics that behave in a predictable regenerative capacity
in vivo. In general, high donor-to-donor variability exists
among hASC donor cell lines. In a laboratory setting, it is
simple enough to select lines that generally express a high
level of potency toward osteo- and/or adipogenic lineages. In
contrast, when considering autologous replacement therapies
in a clinical setting, one does not have the luxury of selecting
for potency. It is therefore important to evaluate hASC with
both high and low differentiation potential for osteogenic,
adipogenic, and/or other lineages of interest.
Four to five donor cell lines were chosen as contributing
cell populations to each superlot. Before selecting the spe-
cific donor hASC lines, candidate cells were qualitatively
rated as strong, moderate, or poor differentiators as desig-
nated by their characteristic staining for osteogenic differ-
entiation or adipogenic differentiation with Alizarin Red S
or Oil Red O, respectively (Fig. 2). Following this qualita-
tive ranking, a combination of strong, moderate, and poor
differentiator hASC lines was selected to compose each age-
grouped superlot with the goal of generating a cell popu-
lation that would represent the average hASC differentiation
potential of a particular age group, that is, pre-, peri-, and
postmenopausal (Table 1 and Figure 3).
To create each superlot, each individual donor cell line
was expanded to 80% confluency in the CGM with medium
changes every 3–4 days. Once each cell line reached 80%
confluency, cells were trypsinized, counted, and combined
in equal proportions into a mixed superlot cell population.
For one single 75 cm2 flask, 1 · 105 total hASC were seeded
FIG. 1. Characterization and validation procedure used to evaluate freshly isolated human adipose-derived stem cells (hASC)
lines. hASC seeded in a six-well plate are grown in the complete growth medium (CGM), osteogenic differentiation medium
(ODM), and adipogenic differentiation medium (ADM), two wells per medium treatment, in columns. Following 14 days of
culture, the hASC are then fixed and stained with Alizarin Red S indicating cell-mediated calcium accretion or Oil Red
O indicating formation of lipid droplets, hallmarks of osteogenesis and adipogenesis, respectively. CGM wells provide a
benchmark control to evaluate hASC responses to differentiation media and to ensure hASC are not undergoing random
differentiation in the absence of induction factors. To further confirm the hASC are undergoing appropriate differentiation, cross
staining of Alizarin Red S to ADM-cultured hASC and Oil Red O to ODM-cultured hASC was used to check for aberrant staining.
Scale bar = 500mm. hASC, human adipose-derived stem cells. Color images available online at www.liebertpub.com/tec
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per flask; therefore, 2 · 104 cells from each hASC donor cell
line were added to create a five-donor cell line superlot for
each of the pre- and postmenopausal superlots (Fig. 3). For
the perimenopausal four-donor superlots, the proportions
were adjusted accordingly with 2.5 · 104 cells per line to a
total of 1 · 105 cells in one 75 cm2 flask.
Validating superlots
The differentiation potential and proliferative activity
of each individual donor and superlot cell line were then
evaluated to validate the representative behavior of the
pooled donor superlots. The proliferative activity was
FIG. 2. Qualitative potency
characterization system.
Once a freshly isolated donor
hASC line has been vali-
dated, its differentiation po-
tential is qualitatively ranked
on a scale from one to five
stars. Chart shows examples
of high-, intermediate-, and
low-level differentiators,
from top to bottom, and their
relative osteogenic (left) and
adipogenic (right) potency
ranking. Scale bar = 500mm.
Color images available on-
line at www.liebertpub
.com/tec















1 36 F Other Adipose 1.5 3.5
2 36 F Caucasian Adipose 3.5 3
3 24 F Caucasian Adipose (liposuction) 1.5 4
4 29 F Native American Adipose 2 2.5
5 34 F Caucasian Adipose 1.5 3
Perimenopausal
6 48 F Caucasian Adipose (liposuction) 1 1.5
7 50 F Caucasian Adipose 2 2
8 55 F Unreported Adipose 2 1
9 49 F Caucasian Adipose 3 2
Postmenopausal
10 60 F Caucasian Adipose (surgical removal) 3 3
11 60 F African American Adipose (panniculectomy) 1 2
12 70 F Unreported Adipose (abdominoplasty) 1.5 3.5
13 81 F Caucasian Adipose 3.5 2
14 61 F Caucasian Adipose (abdominoplasty) 3 1
Age and gender information was supplied for all hASC lines used in this study. Characterization of all 14 donor lines, as described in Figure 1,
was used to validate hASC lines. Donor hASC differentiation potential was ranked on a scale from 1 to 5 as represented in Figure 2. Information
on patient ethnicity and the surgical procedure from which the hASC were derived from were included in the chart, where available.
hASC, human adipose-derived stem cells.
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evaluated using the alamarBlue assay (AbD Serotech). The
differentiation potential was measured qualitatively using
Alizarin Red S to stain calcium deposits indicating osteo-
genesis, and Oil Red O to stain lipid droplets, indicating
adipogenesis, following 14 days of differentiation and fix-
ation in a 10% buffered formalin solution. Differentiation
images were captured using a Leica EZ4 D Digital Stereo-
microscope (Leica Microsystems, Inc.). Additionally, col-
orimetric absorbance assays were used to quantitatively
measure osteogenesis and adipogenesis on a Tecan Micro-
plate Reader (Tecan Group Ltd.) using the Magellan Data
Analysis Software (Tecan Group Ltd.). To measure osteo-
genesis, cell lysates were collected in 0.5 N HCl, and cal-
cium was extracted through mild agitation overnight at 4C.
To measure adipogenesis, a lipid extraction buffer was used
to extract lipids from accumulated lipid vacuoles in adi-
pogenically differentiated hASC. A Calcium LiquiColor
Assay (StanBio) was used to analyze osteogenesis through
calcium accretion, and a colorimetric adipogenesis assay
(BioVision) was used to measure lipid accumulation. The
levels of calcium accretion and lipid accumulation of the
individual cell lines were compared with those of the su-
perlots to investigate the behavior of the pooled samples
relative to hASC from each individual donor.
Measuring DNA and protein content
The total DNA and protein content were measured to
analyze the total cell number and physiological changes in
osteogenically differentiated hASC in relation to both age
and culture within a superlot. To measure the DNA content,
osteogenically differentiated hASC were lysed in a papain
digest DNA lysis buffer (5 mM EDTA, 5 mM cysteine HCl,
and 2.5 U papain/mL in phosphate-buffered saline). The
DNA content was measured under fluorescence on a Tecan
Microplate Reader (Tecan Group Ltd.) using 0.2 mg/mL
Hoechst 33258 dye (Molecular Probes). To measure the
protein content, cells were collected in 0.5 N HCl and the
protein content of hASC lysates was measured using a
colorimetric BCA absorbance assay (Thermo Scientific
Pierce).
Statistical analysis
Statistical analysis was performed using Prism 5 for Mac
OS X, Version 5.0a (GraphPad Software, Inc.). A one-way
analysis of variance with a Newman–Keuls multiple com-
parison post hoc test was used to analyze statistical differ-
ence and to identify statistical significance among sample
conditions. For each individual donor condition, n = 3 rep-
licates. Pre- and postmenopausal groups had n = 5 individual
donors and perimenopausal had n = 4 individual donors.
Statistical significance is indicated as follows: *p < 0.05,
**p < 0.01, and ***p < 0.001.
Results
To ensure that all cell lines were propagating in the
pooled superlot cultures, we analyzed the proliferation
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hASC are isolated from the 
discarded tissue and 
expanded in culture based on 
established protocols.
Superlots are created by  
adding an equal number of 
cells from each donor hASC 
line into culture vessel.
Each pooled donor superlot is 
expanded and validated to  
confirm differentiation
behavior by repeating the 
assay described inFigure 1. 
Each donor hASC line is 
then characterized and 
validated for differentiation
potential (as described in 
Figure1). 
FIG. 3. Schematic de-
scribing isolation procedure
of individual hASC donor
cell lines, their characteriza-
tion, and subsequent genera-
tion of age-matched
superlots. Color images
available online at www
.liebertpub.com/tec
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the superlots. We analyzed the pre-, peri-, and postmeno-
pausal age groups to see if there were any notable differ-
ences in the proliferation rates as measured by alamarBlue,
indicative of metabolic activity (Fig. 4). In general, the
proliferation profile of the superlots fell roughly within the
range of all the individual cells lines for the pre-, peri-, and
postmenopausal clusters (Fig. 4). There was no noticeable
difference in the proliferation rate between the two age
groups; however, there were differences among specific
donor cell lines in pre-, peri-, and postmenopausal groups,
suggesting that hASC proliferation is donor specific as op-
posed to age related.
High donor-to-donor variability generally existed in both
osteogenic and adipogenic differentiation levels among all
the three age groupings (Figs. 5 and 6). Osteogenic levels
for individual donors ranged from 0.0179 to 11.63 calcium/
DNA for premenopausal cell lines, from 0.548 to 2.489
calcium/DNA for perimenopausal cell lines, and from 0.548
to 16.030 calcium/DNA for postmenopausal cell lines (Fig.
5). Adipogenic values for individual donor cell lines ranged
from 0.8 to 5.0 pmol lipids/mg protein for premenopausal
cell lines, from 0.7 to 2.9 pmol lipids/mg protein for peri-
menopausal cell lines, and from 0.0 to 0.6 pmol lipids/mg
protein for postmenopausal cell lines (Fig. 6). Individual cell
lines did not consistently demonstrate multipotency, but
rather, particular lines exhibited a proclivity for differenti-
ating toward a particular lineage.
Calcium accretion (Fig. 5) and lipid accumulation levels
(Fig. 6) of each of the age-grouped superlots fell within the
range of differentiation levels of each individual donor cell
line contributing to the superlot. This result was generally
observed for all age groups in osteogenesis and adipogen-
esis, roughly validating the principle of pooled donor cell
lines exhibiting the average differentiation behavior of the
combined donor cells. In general, the superlots roughly
approximated the combined average adipogenesis levels of
the individual donor lines. This also followed for the os-
teogenesis of the perimenopausal superlot, however, the pre-
and postmenopausal superlot osteogenic levels were the
exception to this trend with the combined donor averages
(4.035 calcium/DNA and 6.11 calcium/DNA, respectively)
predicting a value twice the superlot calcium accretion
levels of the premenopausal superlot and two-thirds that of
the postmenopusal superlot (1.7822 calcium/DNA and 9.605
calcium/DNA, respectively) (Fig. 5a, c).
Although the high level of donor variability was observed
across all age groups, some general differentiation trends
were observed among age groups. Surprisingly, the post-
menopausal group exhibited higher osteogenic calcium ac-
cretion levels as compared with the pre- ( p < 0.001) and
perimenopausal superlots ( p < 0.001) (Fig. 7a, c–e). Con-
versely, the perimenopausal group had approximately half
the adipogenic lipid accumulation levels of the premeno-
pausal superlot ( p < 0.01), and the postmenopausal superlot
had nearly half of the perimenopausal lipid accumulation
levels (Fig. 7b, f–h).
As hASC undergo osteogenic differentiation, continued
proliferation persists as part of the osteogenic phenotype.
Furthermore, as osteogenesis proceeds, hASC begin to de-
posit extracellular matrix proteins. To evaluate this, we
measured the total DNA and protein content following 14
days of osteogenic differentiation. We found that the total
DNA yield decreased with age (Fig. 8a, c), however, the
total protein yield following osteogenic differentiation in-
creased with age (Fig. 8b, d). This trend was observed both
in the combined donor averages and superlots (Fig. 8). The
consistent trends between superlots and average donor data
further validate the use of superlots to represent the average
FIG. 4. Proliferation profiles of pre- (a), peri- (b), and
postmenopausal (c) donor and superlot cell lines for up to 12
days in an expansion medium (CGM). The proliferation
activity is measured by percent reduction of alamarBlue,
indicative of metabolic activity and increased proliferation.
n = 3 replicates, error bars represent SEM. SEM, standard
error of the mean. Color images available online at www
.liebertpub.com/tec
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FIG. 5. Osteogenic differentiation of pre- (a), peri- (b),
and postmenopausal (c) donor lines and superlots following
14 days of culture in ODM. Calcium accretion is normalized
to DNA content for individual donor lines contributing to
each age-matched superlot. Red line indicates the combined
average calcium/DNA value of the contributing donor lines,
which represents the theoretical reference value for the
calcium/DNA superlot value. High donor-to-donor variation
is observed across age groups. n = 3 replicates per donor or
superlot, error bars represent SEM.
FIG. 6. Adipogenic differentiation of pre- (a), peri- (b),
and postmenopausal (c) donor lines and superlots following
14 days of culture in ADM. Lipid accumulation levels
normalized to protein for individual donor lines contributing
to each age-matched superlot. Red line indicates the com-
bined average lipid/protein value of the contributing donor
lines, representing the theoretical value for the lipid/protein
superlot value. High donor-to-donor variation is observed
within age groups. Generally, donor hASC derived from
older patients expressed reduced potential for adipogenic
differentiation, particularly, the postmenopausal group. n = 3
replicates per donor or superlot, error bars represent SEM.
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behavior of individual donors. They also provide a useful
tool in highlighting age-related differences in the physiology
of hASC undergoing osteogenic differentiation (Fig. 8).
Discussion
The goal of this article was to evaluate and present a
method to more efficiently execute studies using hASC to
facilitate their eventual use in clinical applications. More
specifically, we presented an approach to globally understand
hASC as a cell type and to more effectively evaluate their
potential as an autologous cell source in tissue replacement
therapies. A majority of studies reporting data on hASC use
preselected donor cell lines known to be strong differentiators
and often hASC characterized as poor differentiators are
excluded from experimental cell sources.24,25 More recently,
some investigators have been utilizing commercially avail-
able hASC superlots or have been preparing them in-house;
however, there is a dearth of data characterizing the effects of
propagating these mixed donor cell populations. Clearly,
studying pooled cell populations will significantly increase
throughput, but validating their differentiation potential in a
mixed donor population is critical to drawing results from
more sophisticated hASC superlot studies.
To effectively understand the physiological behavior of
hASC for clinical applications, it is necessary to study the
range of their differentiation capacities. To address this is-
sue, we have used the approach of generating superlots,
containing four to five age-clustered pooled cell populations.
In our superlots, we preselected cell lines that were char-
acterized to include low-, medium-, and high-level differ-
entiators (Fig. 2 and Table 1), to determine whether they
would accurately exhibit a differentiation pattern charac-
teristic of the combined average of the individual cell lines.
When compared with the osteogenic and adipogenic dif-
ferentiation levels of each individual donor, the superlot
differentiation levels generally approximated the average
value of all the individual donors, with the exception of
calcium accretion of the pre- and perimenopausal superlots
(Figs. 5 and 6). For most part, we confirmed our expected
result, suggesting that there is likely a minimal reactivity
between cells from different donors. Moreover, this also
suggests that the proportion of each donor cell population
remains roughly equal following propagation and differen-
tiation. This is further supported by only nominal differ-
ences in the proliferation profiles among hASC donors
across age groups and the fact that the superlot proliferation
profiles fit within the range of donor profiles (Fig. 4).
The caveat to utilizing the superlots can be observed in
the case of the pre- and postmenopausal superlots expres-
sing calcium accretion levels notably below or above the
predicted combined average, respectively. The premeno-
pausal superlot underperformed, while the postmenopausal
overperformed in representing the consensus osteogenic
differentiation level of the group, with the premenopausal
expressing approximately half the expected level of average
calcium accretion (Fig. 5a) and the postmenopausal superlot
expressing an *30% increase compared with the predicted
average (Fig. 5c). We speculate that the large difference
between the expected average combined donor value and the
superlot value of calcium may be skewed due to specific
donor lines accreting little to no calcium over the course of
a 14-day differentiation. This particularly comes into play
when normalizing to the DNA content, which is
FIG. 7. Summary of pre-, peri-, and postmenopausal superlot potency. Osteogenic differentiation as measured quanti-
tatively by Calcium Liquicolor Assay (a) and adipogenic differentiation as measured by lipid accumulation assay (b),
following 14 days of culture in ODM and ADM, respectively. Alizarin Red S staining to visualize superlot osteogenesis
through calcium accretion of pre- (c), peri- (d), and postmenopausal (e) superlots. Oil Red O staining to visualize superlot
adipogenesis through lipid droplet staining of pre- (f), peri- (g), and postmenopausal (h) superlots. n = 3 replicates per
superlot, error bars represent SEM. Scale bar = 500mm. *p < 0.05; ***p < 0.001. Color images available online at
www.liebertpub.com/tec
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proportional to the number of cells in culture. Human
ASC growing in culture, expressing minimal calcium
have the potential to significantly reduce the calcium/
DNA ratio. Moreover, the general cell-lineage specification
paradigm proposes that proliferation and differentiation are
somewhat opposing processes.26 Once a cell population be-
gins to undergo differentiation, its proliferation activity is
impeded. However, it may be possible that the proliferative
activity remains higher through day 14 for donor hASC that
show little to no evidence of osteogenic differentiation,
skewing the calcium/DNA data. These results are corrobo-
rated by the high level of DNA content in premenopausal
donors and the relatively low level of DNA in postmenopausal
donors, following 14 days of differentiation (Fig. 8a, c). In-
terestingly, this issue did not affect donor lines undergoing
adipogenic differentiation, but this may also be due to the
lowered metabolic activity of the adipogenic phenotype and
the media formulation. We have observed that hASC cultured
under the ODM tend to persist in a proliferative capacity
slightly longer than hASC cultured under the ADM. This
could also be related to lineage-specific metabolic and phys-
iologic processes resulting in hASC quiescence/senescence
under induction of lineage commitment.12,14 The skewing of
the osteogenic superlot data may hint that hASC exhibiting
minimal to no evidence of calcium accretion express cell
physiologies preventing them from undergoing osteogenesis
and/or accreting calcium. Therefore, it is critical that investi-
gators utilizing pooled hASC superlots proceed with cau-
tion—acknowledging that the superlot cell populations have a
higher level of heterogeneity compared with single donors,
which can affect the outcome of studies.
Despite the skewed pre- and postmenopausal data, there
is considerable value in employing superlots containing
donor lines with differing potencies. The reasoning for se-
lecting this range of potency levels within our cell lines was
to begin to glean potency information of a typical hASC.
Extending this thinking further, using superlots, may facil-
itate prediction of the differentiation potential for an average
patient’s hASC. Since hASC are so extensively studied for
their promise as an autologous cell source for tissue re-
placement therapies, it is important to acquire practical data
that can be more directly translated into the clinic. That is to
say, every patient will not have hASC with a high level of
multipotency or hASC that exhibit high proclivity toward
FIG. 8. Total DNA and protein content levels in age-clustered groups. Following 14 days of osteogenic differentiation,
total DNA (a, c) and protein (b, d) content were measured for each individual donor cell line and superlots. Top row graphs
represent the average DNA (a) and protein (b) content of individual cell lines (n = 5 donors for pre- and postmenopausal,
n = 4 donors for perimenopausal). Bottom row graphs represent DNA (c) and protein (d) content of each each superlot (n = 3
replicates for each superlot). Error bars represent SEM.
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the desired cell lineage. Through studying the hASC su-
perlot differentiation activity, investigators can begin to
profile the average patient, and subsequently hone research
approaches to address the limitations of the hASC source.
In addition to using a superlot approach to characterize
the typical patient hASC population, we thought it necessary
to highlight the extreme differences among hASC donor cell
differentiation potential. This is not only clinically relevant
information but suggests that as investigators we should
evaluate reported data with a critical eye. In the future it
may be necessary to develop a classification system to
identify predictors of differentiation potential. Although
some work has been done profiling hASC using cell surface
markers,6,27 microarray surveys of gene expression,28,29 and
microRNA profiles,12 these data have not been extensively
correlated with hASC potency. It is important to note that
the ages and number of donor cell lines incorporated in this
study were based on the availability of donor cell lines
within our laboratory bank of cells. Due to isolating and
maintaining our own cell bank, the number of contributing
donor cell lines and the range of ages incorporated are
limitations of this study. It is additionally important to
consider the in vivo differentiation capacity of hASC. This
study describes a method to consider donor-specific effects
on hASC differentiation, toward the goal of clinically em-
ploying them in tissue engineering applications, however,
we only consider their in vitro differentiation capacity. The
differentiation behavior of hASC derived from donors of a
specific age, and that of superlots, will need to be further
investigated to elucidate the valid application of these data
within in vivo model systems.
According to our data, which display a high degree of
donor-to-donor variability, regardless of age, we suggest
that a method for baseline characterization of hASC be re-
ported along with donor patient data. Stark differences were
observed among the relative differentiation capacities of
pre-, peri-, and postmenopausal age groups and the trends
were contrary to what was expected, showing the youngest
group expressing the highest proclivity for adipogenic dif-
ferentiation and the oldest group expressing the highest
proclivity for osteogenesis (Fig. 7). These findings are
consistent with other human and animal ASC studies ex-
hibiting a decrease in adipogenesis with age.16,17 Interest-
ingly, our osteogenesis results showing increased calcium
accretion in the postmenopausal age group are consistent
with work in human mesenchymal stem cells derived from
osteoporotic postmenopausal donors.19 However, the effect
of age on hASC differentiation, particularly osteogenesis,
has been largely debated in the literature.9,12,14,16
In addition to variations in hASC potency with age, hASC
also exhibit age-related changes in total DNA and protein
content with age, following 14 days of osteogenic differ-
entiation (Fig. 8). Generally, premenopausal hASC ex-
hibited the highest DNA content following 14 days of
osteogenesis, while postmenopausal cells had the highest
level of protein. This may, in part, explain the lowered level
of osteogenesis as this may indicate higher proliferation of
hASC derived from younger patients, thus slowing the lin-
eage commitment process, while hASC derived from post-
menopausal donors slow their proliferation as evidenced by
a relatively lowered DNA content (Fig. 8a, c). This is further
corroborated by the fact that hASC derived from postmen-
opausal donors exhibited relatively higher total protein
values than pre- and perimenopausal cell lines following 14
days of osteogenesis, which may be indicative of increased
extracellular matrix production, a hallmark of osteogenesis
(Fig. 8b, d). It is important to note that when hASC are
cultured under expansion media for up to 12 days, the
proliferation profile among age groups does not vary dras-
tically (Fig. 4), suggesting that these changes are specifically
related to hASC developing the osteogenic phenotype.
Our data suggest that there may be age-related changes in
hASC potency, which are likely related to physiological
changes associated with menopause. It should be noted that,
with the limitations of our study and our currently cata-
logued cell bank, we only grouped our age-matched super-
lots based on the average purported age of menopausal
phases, and supplied patient information did not include
menopausal information. With that general information, we
do hypothesize that these hASC potency changes may be
related to the physiological changes in the body such as a
lowering of bone density and osteoblast/osteoclast activity
already known to affect women following menopause.30
However, we propose that to generate more informative
age-related studies in the future, it would be valuable to
acquire female patient information on the menopausal
phase. Having this information would allow hASC studies to
report more definitive results on the differentiation potential
of hASC and further the capacity and limitations of their
therapeutic applications. Although there is a strong rela-
tionship between the menopausal phase and bone density
and physiology, the age-matched hASC superlot approach
proposes a streamlined tactic to predict the behavior of
tissue-engineered constructs of other musculoskeletal tissues
such as cartilage, tendon, and muscle. In the case of other
tissues, it may be useful to cluster the ages of the donors
around critical developmental phases for a given tissue and/
or even to develop specific donor patient criteria to select for
characteristics beneficial to a particular lineage. This study
is the first step in building this approach.
It should be noted that this study focuses on in vitro be-
havior of superlots, however, it is unclear whether superlots
can predict hASC differentiation when used in studies in
which hASC are implanted in vivo. Exploring the use of su-
perlots supports the goal of utilizing hASC for autologous
tissue replacements although the cells are derived from
many patients and there is potential for an immune response.
Nonetheless, their potential to streamline hASC studies and
increase throughput is clear, and thus their in vivo character-
ization may be a critical next step to validating their efficacy.
One final caveat to this study, and a majority of hASC
studies in the literature that should be noted, is that hASC are
largely sourced from overweight to severely obese patients.
The hASC in our cell banks are obtained from discarded
tissue derived from abdominoplasty, panniculectomy, or li-
posuction tissue. Although all three procedures are techni-
cally cosmetic surgery, we do not have patient body mass
index (BMI) or weight data, and thus, little indication of the
patient’s health status. It is likely that hASC derived from
healthy patients will exhibit a different differentiation profile
from those derived from severely obese patients.31,32 Other
sources of variation may include the specific medical pro-
cedure with which a tissue was obtained, however, it is likely
that patient physiology may have the greatest influence. This
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may partially explain the high level of donor-to-donor vari-
ation across age groups. Understanding the source of the
differential hASC potencies is essential to applying hASC in
clinical procedures.
In conclusion, we have described a method for generating
age-matched pooled donor cell lines to produce hASC su-
perlots containing cells from four to five donors. We have
demonstrated that the hASC can proliferate and differentiate
in these pooled donor cell environments and that they ex-
hibit the combined average osteogenic and adipogenic dif-
ferentiation levels of each donor cell line. Furthermore, we
highlight the high degree of donor-to-donor variation in
differentiation capability that occurs among donor cell lines
and suggest that superlots may be a way to circumvent this
issue when generating experimental data. We do, however,
suggest that researchers proceed with caution in determining
whether their particular study is best suited for analyses
using individual donor hASC lines or hASC superlots. Ei-
ther approach will depend, of course, on the particular sci-
entific question being asked. That being said, we propose
that hASC superlots are a powerful tool to study hASC, and
may provide an efficient way to increase data throughput to
facilitate hASC use in clinical applications.
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